Yong Song

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 423 citations

Medicine, Oncology, Pharmacology +6

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 396 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Yuankai Shi, L. Wang, Baohui Han et al. · Annals of Oncology · 2017 · 338 citations

Medicine, Oncology, Pharmacotherapy +10

Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non‑small cell lung cancer

Jianwei Gao, Xiangyu Qiu, Guangmin Xi et al. · Oncology Reports · 2018 · 280 citations · Full text

Medicine, Cancer Biology, Oncology +17

Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer

Tangfeng Lv, Dongmei Yuan, Xiaohui Miao et al. · PLoS ONE · 2012 · 269 citations · Full text

Medicine, Molecular Biology, Oncology +17